BRIEF

on NanoViricides, Inc. (NASDAQ:NNVC)

NanoViricides Reports Progress in NV-387 Clinical Trials

NanoViricides, Inc. has made significant strides with the broad-spectrum antiviral drug NV-387. According to their recent quarterly report for September 2026, two Phase II clinical trials have begun for NV-387, targeting Ebola Bundibugyo Virus and Mpox (Monkeypox). These trials are noteworthy since there are currently no licensed drugs for these virus strains.

For Ebola, enrollment commenced on September 23, 2026, driven by a WHO emergency declaration due to rising cases and deaths. Mpox trials began the same day, addressing the absence of effective treatments for Clade I and II strains. Notably, existing clinical trials for treatments like tecovirimat have not shown promising results.

Additionally, the company's financial report reveals challenges ahead. As of September 2026, their cash reserves stand at $2.98 million, insufficient to sustain operations through November 2027 without additional funding.

R. P.

Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.

Click here to consult the press release on which this article is based

See all NanoViricides, Inc. news